Roivant
GSK confirms £250m deal to sell experimental drug to Dermavent Sciences
July 13, 2018Medical Communications Dermavent, GSK, Roivant, tapinarof
British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ …
Roivant launches two new companies amid major restructure and staff layoffs
June 26, 2018Manufacturing and Production, Research and Development Roivant, pharma
Roivant, the global biopharmaceutical firm spearheaded by founder and CEO Vivek Ramaswamy (pictured), has announced it is to undergo a …
Roivant signs $600m licensing deal with Poxel
February 13, 2018Manufacturing and Production, Sales and Marketing Poxel, Roivant, diabetes, imeglimin, pharma
Roivant Sciences has announced that it has entered into a licensing partnership with Poxel to develop and commercialise the latter’s …
Axovant’s drug bested by placebo, shares reduced to dust
January 8, 2018Manufacturing and Production, Research and Development Axovant, Roivant, biotech, dementia, drugs, pharma, pharmaceutical
The signs were already there for Axovant Sciences’ key drug, intepirdine, when it posted poor results from a recent study …
Japanese telecom giant injects $1.1bn into Swiss biotech in largest-ever investment of its kind
August 10, 2017Sales and Marketing Roivant, SoftBank, biotech, life sciences, medicine, pharma, pharmaceuticals
In possibly the biggest single biotech investment ever made, Swiss biotech firm Roivant has received a $1.1 billion cash injection …
Latest content
